Targeted & controlled bone healing
26 Jun 19
Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure

Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure

Schlieren (Zurich), Switzerland, June 26, 2019 – On July 17, at its upcoming extraordinary general meeting of shareholders, Kuros Biosciences (SIX: KURN) will propose that:

 

The Authorized Share Capital shall be increased and adapted from currently 1'592'246 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.


The Conditional Share Capital for Bonds or Similar Debt Instruments shall be increased from cur-rently 1'720'585 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.


The Conditional Share Capital for Employees, Persons of Comparable Positions and Board Mem-bers shall be increased from currently 1'389'647 to 2'248'389 registered shares with a nominal value of CHF 1.00 each


Documents for the EGM, including the Information Notice with a full agenda, will be made availa-ble online on June 26th at: http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_e_2019.pdf



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
26 Jun 19
Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure

Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure

Schlieren (Zurich), Switzerland, June 26, 2019 – On July 17, at its upcoming extraordinary general meeting of shareholders, Kuros Biosciences (SIX: KURN) will propose that:

 

The Authorized Share Capital shall be increased and adapted from currently 1'592'246 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.


The Conditional Share Capital for Bonds or Similar Debt Instruments shall be increased from cur-rently 1'720'585 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.


The Conditional Share Capital for Employees, Persons of Comparable Positions and Board Mem-bers shall be increased from currently 1'389'647 to 2'248'389 registered shares with a nominal value of CHF 1.00 each


Documents for the EGM, including the Information Notice with a full agenda, will be made availa-ble online on June 26th at: http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_e_2019.pdf